Letfem Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor indicated primarily for the treatment of hormone receptor-positive breast cancer in postmenopausal women. By selectively inhibiting the aromatase enzyme, Letrozole reduces peripheral estrogen synthesis, thereby lowering circulating estrogen levels that can stimulate the growth of estrogen-dependent breast cancer cells. Letfem Tablet is commonly prescribed as adjuvant therapy following surgery or radiotherapy, as well as for advanced or metastatic breast cancer to delay disease progression. The recommended dosage is one 2.5 mg tablet once daily, with or without food, as directed by a healthcare professional. Patients should be monitored regularly for bone mineral density, lipid profile alterations, and potential adverse effects such as hot flashes, arthralgia, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment, and Letfem is contraindicated during pregnancy and lactation due to potential teratogenic effects. Letfem Tablet should be used under strict medical supervision, with periodic assessment to evaluate therapeutic response and tolerability. Adherence to prescribed dosage and follow-up schedules is essential to optimize clinical outcomes and minimize risks associated with estrogen deprivation.